Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 15-Deoxyspergualin; BMS 181173; BMY 422151; Deoxyspergualin; Deoxyspurgiline; DSG; Heptanamide; NKT 301; NKT-01; NSC 356894; Spandin injection; Spandin®; Spanidin; Spanidin injection

Latest Information Update: 03 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Nippon Kayaku; Nordic Group
  • Class Cytostatic antibiotics; Guanidines; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wegener's granulomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Wegener's granulomatosis
  • Discontinued Cancer; Diabetes mellitus; Glomerulonephritis; Hypersensitivity; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2014 Nordic Pharma suspends enrolment in the phase III SPARROW trial for Wegener's granulomatosis in Czech Republic, Germany, Sweden and Spain (NCT01446211)
  • 19 Jan 2012 Phase-III clinical trials in Wegener's granulomatosis (recurrent) in Germany, Sweden, Spain and United Kingdom (SC) after January 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top